Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

Abstract

These results suggest that under the right framework and when panels are used, the in vitro cell line and human xenograft models may be useful in predicting the Phase II clinical trial performance of cancer drugs. Murine allograft models, as used in this analysis, appear of limited utility.